Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bolus-pCINC Study: Sodium Bicarbonate Bolus to Prevent Contrast-Induced Nephropathy After Emergency PCI
jRCTs051210170Completed
- Sponsor
- Otsuka Holdings
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sodium bicarbonate in contrast-induced nephropathy (CIN) and myocardial infarction (MI), sponsored by Otsuka Holdings. Primary endpoint: Primary endpoint: CIN within 48 ± 12 hours. Started Feb 2022; status: completed.
02
Drugs
sodium bicarbonate
03
Conditions
contrast-induced nephropathy (CIN)myocardial infarction (MI)
Beyond the preview
Go deeper on jRCTs051210170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210170.